on ABL DIAGNOSTICS (EPA:ABLD)
ABL Diagnostics and CDL Pharma Secure €2.7 Million Contract
ABL Diagnostics has announced a significant multi-year contract with a European pharmaceutical firm, focusing on neurodegenerative diseases, potentially worth €2.7 million by 2031. The collaboration involves services operated by CDL Pharma and distributed by ABL Diagnostics, highlighting their role in an international clinical program spanning 11 countries.
Initial payment upon contract signing exceeds €100,000, with revenue recognition based on service performance, dependent on the clinical program's progress. CDL Pharma will handle the operational management of trials, logistics, sample analysis, while ABL Diagnostics distributes these services.
This contract boosts future revenue visibility and showcases the growth of ABL Diagnostics' services in clinical research. Market trends in neurodegenerative diseases, driven by aging populations, foresee a potential market size of USD 88 billion by 2030-2031.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABL DIAGNOSTICS news